Medigene to Participate in Five Investment and Scientific Conferences in November
(Thomson Reuters ONE) -
Medigene AG /
Medigene to Participate in Five Investment and Scientific Conferences in
November
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Press Release
Martinsried/Munich, 3 November, 2014. Medigene AG (MDG1, Frankfurt, Prime
Standard) announces its participation in five international conferences:
* BIO-Europe - Annual International Partnering Conference
Date: 3 - 5 November 2014
Location: Frankfurt am Main, Germany
* The Society for Immunotherapy of Cancer (SITC)
Date: 7 - 9 November 2014
Location: National Harbor (Washington D.C.), USA
Poster Presentation on 8 November focusing the TCR immunotherapy platform titled
"Generation of tumor antigen-specific CD4+ and CD8+ T cells by simultaneous MHC-
I and -II epitope presentation in vitro and in vivo"
* Jefferies Global Healthcare Conference
Date: 19 - 20 November 2014
Location: London, Great Britain
* German Equity Forum
Date: 24 - 26 November 2014
Location: Frankfurt am Main, Germany
Company Presentation at 25 November 5 pm
* BayImmuNet - International Symposium on Interventional Immunology from Cells
to Drugs
Date: 13 - 14 November 2014
Location: Regensburg, Germany
Chair: Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology
company headquartered in Martinsried near Munich, Germany. Medigene concentrates
on the development of personalized T cell immunotherapies with a focus on
haematological malignancies. Medigene is the first German biotech company to
have revenues from a marketed product, which is distributed by commercial
partner companies. Medigene has advanced drug candidates which are licensed to
partners and additional candidates in clinical development. The company is
developing highly innovative treatment platforms concentrating on cancer and
autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) EndoTAG(®) and Veregen(® )are registered trademarks of Medigene AG.
These trademarks may be owned or licensed in select locations only.
Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please visit:
http://www.medigene.de/unsubscribe
Press release as PDF:
http://hugin.info/132073/R/1867724/656331.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
[HUG#1867724]
Unternehmensinformation / Kurzprofil:
Datum: 03.11.2014 - 08:00 Uhr
Sprache: Deutsch
News-ID 348933
Anzahl Zeichen: 3789
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 131 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene to Participate in Five Investment and Scientific Conferences in November"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
